PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors
- Conditions
- Neoplasms
- Interventions
- Drug: PF-05212384 (also known as PKI-587)
- First Posted Date
- 2009-07-16
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 78
- Registration Number
- NCT00940498
- Locations
- 🇬🇧
King's College London, London, England, United Kingdom
🇺🇸Dana-Farber Cancer Insitute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease
- First Posted Date
- 2009-07-15
- Last Posted Date
- 2012-11-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 649
- Registration Number
- NCT00939783
- Locations
- 🇵🇷
Pfizer Investigational Site, San Juan, Puerto Rico
Relative Drug Exposures Of Two Formulations of PF-02341066
- First Posted Date
- 2009-07-15
- Last Posted Date
- 2011-10-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00939731
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects
- First Posted Date
- 2009-07-15
- Last Posted Date
- 2010-02-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00940017
- Locations
- 🇺🇸
Pfizer Investigational Site, Hartford, Connecticut, United States
A Study Of Kappa Opioid Receptor Occupancy Of PF-04455242, Using PET (Positron Emission Tomography)
- First Posted Date
- 2009-07-15
- Last Posted Date
- 2010-02-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT00939887
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Bioequivalence Between Two Tablet Formulations Of Doxycycline Carragenate
- Conditions
- Bacterial Infection
- Interventions
- First Posted Date
- 2009-07-15
- Last Posted Date
- 2009-12-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00939562
- Locations
- 🇮🇳
Pfizer Investigational Site, Ahmedabad, Gujarat, India
A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: PF-04171327 10 mgDrug: PF-04171327 25 mgOther: PlaceboOther: Prednisone PlaceboOther: Placebo for PF-04171327
- First Posted Date
- 2009-07-14
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 86
- Registration Number
- NCT00938587
- Locations
- 🇭🇺
MAV Korhaz es Rendelointezet, Szolnok, Hungary
🇨🇿Revmatologicka ambulance, Praha 4, Czechia
🇺🇸Anniston Medical Clinic, PC, Anniston, Alabama, United States
Compliance And Safety Study In Children With Upper And Lower Respiratory Tract Infections
- First Posted Date
- 2009-07-14
- Last Posted Date
- 2010-03-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 400
- Registration Number
- NCT00939185
Study Evaluating Safety and Adherence to Treatment With Etanercept in Adults With Psoriatic Arthritis
- Conditions
- Arthritis, Psoriatic
- Interventions
- Other: Questionnaire
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 303
- Registration Number
- NCT00938015
- Locations
- 🇧🇪
Pfizer Investigational Site, Leuven, Belgium
A First In Human Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Single Rising Doses In Healthy Adult Volunteers
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2009-10-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT00938301
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States